TOBRAMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H37N5O9
Molecular Weight	467.5145
Optical Activity	UNSPECIFIED
Defined Stereocenters	14 / 14
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O[C@@]2([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O)[C@H]1O)O[C@H](CN)[C@@H](O)C[C@H]3N

InChI

InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N

InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H37N5O9
Molecular Weight	467.5145
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	14 / 14
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf
Curator's Comment: Description was created based on several resourses, including http://www.drugbank.ca/drugs/DB00684

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
30S ribosomal protein S12 19 Target ID: CHEMBL1641336 Sources: http://www.drugbank.ca/drugs/DB00684#targets	Inhibitor 8228		9.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
External infections of the eye 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50541slr017_tobrex_lbl.pdf	Curative		Approved 8360	TOBREX Approved Use external infections of the eye Launch Date 3.45427214E11
Cystic fibrosis 120 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf	Primary		Approved 8360	KITABIS PAK Approved Use cystic fibrosis Launch Date 1.39216316E12

C_max

Value	Dose	Co-administered	Analyte	Population
3.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
814 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
11.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12 mg/kg 1 times / day multiple, intravenous (mean) Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	unhealthy, 2 months - 27 years Health Status: unhealthy Condition: cystic fibrosis Age Group: 2 months - 27 years Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	Sources: https://pubmed.ncbi.nlm.nih.gov/6440126
300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	Other AEs: Forced expiratory volume decreased, Rales... Other AEs: Forced expiratory volume decreased (31%) Rales (19%) Red blood cell sedimentation rate increased (8%) Dysphonia (6%) Wheezing (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	Other AEs: Hypersensitivity, Eyelids itchy sensation of... Other AEs: Hypersensitivity Eyelids itchy sensation of Swelling Redness of eyelid conjunctiva Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
1.5 mg/kg 3 times / day multiple, intramuscular Dose: 1.5 mg/kg, 3 times / day Route: intramuscular Route: multiple Dose: 1.5 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/820195	unhealthy, adult n = 28 Health Status: unhealthy Condition: gram-negative bacilli infection Age Group: adult Population Size: 28 Sources: https://pubmed.ncbi.nlm.nih.gov/820195	Sources: https://pubmed.ncbi.nlm.nih.gov/820195
2 mg/kg single, intraperitoneal Dose: 2 mg/kg Route: intraperitoneal Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	unhealthy, adult n = 5 Health Status: unhealthy Condition: end stage renal disease Age Group: adult Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	Sources: https://pubmed.ncbi.nlm.nih.gov/3950451

AEs

AE	Significance	Dose	Population
Rales	19%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Forced expiratory volume decreased	31%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Wheezing	5%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Dysphonia	6%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Red blood cell sedimentation rate increased	8%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years n = 190 Health Status: unhealthy Age Group: >6 years Sex: M+F Population Size: 190 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Eyelids itchy sensation of		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Hypersensitivity		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Redness of eyelid conjunctiva		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Swelling		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1437 OAT1 595 OAT3 636 OAT2 144 OATP1B1 781 OATP2B1 122 OCT1 506 OCT2 638	P-gp 1527

Drug as perpetrator

Target	Modality	Activity
OATP1B1 796	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT1 523	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT2 639	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OAT2 146	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	no
OATP2B1 125	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	no
P-gp 1626	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/pii/S0022354921000708 Page: 1612.0	no
OAT1 599	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes
OAT3 638	inhibitor 3240 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1527	substrate 3326 Sources: https://www.sciencedirect.com/science/article/pii/S0024320501013753 Page: 2908.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28864	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28864
ChemicalBook	CB7154445	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7154445
MolPort	MolPort-003-665-548	https://www.molport.com/shop/molecule-link/MolPort-003-665-548
Selleck Chemicals	Tobramycin(free-base)	http://www.selleckchem.com/products/Tobramycin(free-base).html
ZINC	ZINC000008214692	http://zinc15.docking.org/substances/ZINC000008214692
eMolecules	36516853	https://www.emolecules.com/cgi-bin/more?vid=36516853
eMolecules	3716283	https://www.emolecules.com/cgi-bin/more?vid=3716283

PubMed

Title	Date	PubMed
Comparative review of topical ophthalmic antibacterial preparations.	2001	11270936
The effect of apramycin on colonization of pathogenic Escherichia coli in the intestinal tract of chicks.	2001 Apr	11361100
Infectious crystalline keratopathy in an immunosuppressed patient.	2001 Apr	11352447
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs.	2001 Apr	11310518
[Mupirocin resistant MRSA in Japan].	2001 Apr	11304996
Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis.	2001 Apr	11296179
The role of nebulized antibiotics in treating serious respiratory infections.	2001 Aug	11589477
Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site.	2001 Aug	11587639
[Antibiotic resistance of Staphylococcus aureus in urban experience: 6 month study in Aquitaine].	2001 Feb	11265221
Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis.	2001 Feb	11252417
Disseminated Pseudomonas aeruginosa and necrotizing pneumonia with complete recovery.	2001 Feb	11235039
[Adverse effects of transrectal prostatic biopsy. Analysis of 303 procedures].	2001 Jan	11284367
[Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin].	2001 Jan 13	11210578
Applications of a copper microparticle-modified carbon fiber microdisk array electrode for the simultaneous determination of aminoglycoside antibiotics by capillary electrophoresis.	2001 Jan 5	11206799
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.	2001 Jul	11471880
Recent advances in cystic fibrosis.	2001 Jul	11420207
Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials.	2001 Jul 9	11425542
Tobramycin (Cystic Fibrosis Foundation/PathoGenesis).	2001 Jun	11572653
Clinical observation and treatment of leptospirosis.	2001 Jun	11455495
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.	2001 Jun	11397621
Ultraviolet recall-like phenomenon occurring after piperacillin, tobramycin, and ciprofloxacin therapy.	2001 Jun	11369921
Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study.	2001 Jun 1	11380220
Risk of endotoxemia during the initial phase of gut decontamination with antimicrobial agents.	2001 Mar	11426668
Effect of some fractions of alveolar surfactant (phospholipids and SP-A) on the bactericidal activity of different antimicrobials against some respiratory pathogens.	2001 Mar	11318808
Aminoglycoside ototoxicity.	2001 Mar	11300281
[Effect of tobramycin with topical diclofenac on arachidonic acid in endotoxin-induced uveitis].	2001 Mar	11283780
Kinetic and mutagenic characterization of the chromosomally encoded Salmonella enterica AAC(6')-Iy aminoglycoside N-acetyltransferase.	2001 Mar 27	11297438
Statement on the application of the ToBI test for batch potency testing of tetanus vaccines for human use.	2001 Mar-Apr	11379537
Management of corneal epithelial defects following laser in situ keratomileusis.	2001 Mar-Apr	11316020
Natural antibiotic susceptibility of recently established coryneform bacteria.	2001 May	11453591
Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations.	2001 May	11377168
In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers.	2001 May	11349742
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.	2001 May	11340683
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.	2001 Oct	11598606
The treatment of cystic fibrosis--step by step.	2001 Oct	11598588
Bacillus cereus keratitis associated with contact lens wear.	2001 Oct	11581057
Efficacy and safety of aerosolized tobramycin in cystic fibrosis.	2001 Oct	11568993
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.	2001 Oct	11568989
Aminoglycoside binding to human and bacterial A-Site rRNA decoding region constructs.	2001 Oct	11557348
Gene expression in Pseudomonas aeruginosa biofilms.	2001 Oct 25	11677611
High-rising terminals and fall-rise tunes in Australian English.	2001 Oct-Dec	11641630
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey.	2001 Sep	11678929
Isolation and culture of airway epithelial cells from chronically infected human lungs.	2001 Sep	11669281
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].	2001 Sep	11642015
Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin.	2001 Sep	11587466
Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial.	2001 Sep	11555764
Microbiological and immunologic considerations with aerosolized drug delivery.	2001 Sep	11555566
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.	2001 Sep	11549103
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.	2001 Sep	11533004
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.	2001 Sep 22	11583754

Patents

Sample Use Guides

In Vivo Use Guide

KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.

Route of Administration: Respiratory

In Vitro Use Guide

High-dose tobramycin (200 ug/ml) killed 72% of Pseudomonas aeruginosa isolates

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:03:31 UTC 2023` Edited by `admin` on `Wed Jul 05 23:03:31 UTC 2023`
Record UNII	VZ8RRZ51VK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOBRAMYCIN

Official Name

English

TOBRAMYCIN [ORANGE BOOK]

Common Name

English

TOBRASONE COMPONENT TOBRAMYCIN

Common Name

English

TOBRAMYCIN [USP MONOGRAPH]

Common Name

English

ZYLET COMPONENT TOBRAMYCIN

Common Name

English

TOBRAMYCIN COMPONENT OF ZYLET

Common Name

English

TOBRAMYCIN [EP MONOGRAPH]

Common Name

English

TOBREX

Brand Name

English

TOBRAMYCIN [JAN]

Common Name

English

TOBRAMYCIN [HSDB]

Common Name

English

tobramycin [INN]

Common Name

English

NEBRAMYCIN VI

Common Name

English

TOBRAMYCIN [MI]

Common Name

English

TOBRADEX ST COMPONENT TOBRAMYCIN

Common Name

English

AKTOB

Brand Name

English

NEBRAMYCIN FACTOR 6

Common Name

English

TOBRAMYCIN [VANDF]

Common Name

English

47663

Code

English

TOBRAMYCIN COMPONENT OF TOBRADEX

Common Name

English

KITABIS PAK

Brand Name

English

TOBRAMYCIN COMPONENT OF TOBRADEX ST

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4))-2-DEOXY-

Common Name

English

VANTOBRA

Brand Name

English

O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1.ALPHA.6))-2-DEOXY-L-STREPTAMINE

Common Name

English

TOBRAMYCIN COMPONENT OF TOBRASONE

Common Name

English

TOBI PODHALER

Brand Name

English

NSC-180514

Code

English

TOBRAMYCIN [USAN]

Common Name

English

TOBRAMYCIN [MART.]

Common Name

English

TOBRAMYCIN [USP-RS]

Common Name

English

Tobramycin [WHO-DD]

Common Name

English

TOBI

Brand Name

English

TOBRADEX COMPONENT TOBRAMYCIN

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000007853